Leukemia; solid tumors
Human leukocyte antigen (HLA); Wilms tumor 1 (WT1)
Mouse and cell culture
studies suggest a human mAb targeting the WT1-HLA complex could help treat
leukemia and solid tumors. In panels of cells from healthy donors and
patients, the human mAb, called ESK1, bound to the majority of
leukemic and solid tumor cell lines that were positive for WT1 and the
WT1-HLA complex. In a mouse xenograft model for acute lymphoblastic leukemia
(ALL), ESK1 decreased tumor burden and increased survival compared with a
Next steps include evaluating ESK1 in additional animal safety studies and
scaling up manufacturing of the antibody.
Eureka Therapeutics Inc.
has ESK1 in preclinical development to treat leukemia.
GlaxoSmithKline plc's GSK2130579, an
antigen-specific cancer immunotherapeutic utilizing recombinant WT1, is in Phase
II testing to treat acute myelogenous leukemia (AML) and Phase I testing to
treat breast cancer.
Inovio Pharmaceuticals Inc.
has a WT1 DNA vaccine in Phase II testing to treat leukemia (see mAb attack on WT1,
Published online March 28, 2013
Patent applications filed;
available for licensing from Memorial Sloan-Kettering Cancer Center
and Eureka Therapeutics
Contact: Sharon Seiler, Memorial
Sloan-Kettering Cancer Center, New York, N.Y.
Contact: Elisa Pan, Eureka Therapeutics Inc., Emeryville,
Dao, T. et al. Sci.
Transl. Med.; published online March 13, 2013;
Contact: David A. Scheinberg, Memorial Sloan-Kettering
Cancer Center, New York, N.Y.
Contact: Cheng Liu, Eureka Therapeutics Inc., Emeryville,